Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The impact of small molecule inhibition of METTL3 on normal haematopoiesis

ABSTRACT: We performed scRNA-seq on haematoietic stem and progenitor cells of healthy wild-type mice treated with the small-molecule inhibitor of METTL3, STM2457.

ORGANISM(S): Mus musculus

PROVIDER: GSE228562 | GEO | 2023/07/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The impact of small molecule inhibition of METTL3 on normal haematopoiesis

Project description:The impact of small molecule inhibition of METTL3 on normal haematopoiesis

| PRJNA950362 | ENA

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [meRIP-Seq]

Project description:The N6-methyladenosine (m6A) RNA modification is an important regulator of gene expression. m6A is deposited by a methyltransferase complex that includes methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14). High levels of METTL3 and METTL14 drive the growth of many types of adult cancer, and METTL3/METTL14 inhibitors are emerging as new anticancer agents. However, little is known about the m6A epitranscriptome or the role of the METTL3/METTL14 complex in neuroblastoma, a common pediatric cancer. Here, we show that METTL3 knockdown or pharmacologic inhibition with the small molecule STM2457 leads to reduced neuroblastoma cell proliferation and increased differentiation. These changes in neuroblastoma phenotype were associated with decreased m6A deposition on transcripts involved in nervous system development and neuronal differentiation and increased stability and expression of target mRNAs. In preclinical studies, STM2457 treatment suppressed the growth of neuroblastoma tumors in vivo. Together, these results support the potential of METTL3/METTL14 complex inhibition as therapeutic strategy against neuroblastoma.

2024-04-10 | GSE240582 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-Seq Decay]

2024-04-10 | GSE240581 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-seq siMETTL3]

2024-04-10 | GSE263118 | GEO

Small-molecule Inhibition of METTL3 Suppresses Tumor Growth and Promotes Neuroblastoma Differentiation [RNA-Seq STM]

2024-04-10 | GSE262731 | GEO

RNA-seq of human breast cancer cell line MDA-MB-231 treated with STM2457 against untreated controls

Project description:Here, we aim to investigate if catalytic inhibition of the m6A methyltransferase METTL3 by the small-molecule STM2457 may be a viable treatment option for TNBC.

2023-12-18 | E-MTAB-13184 | biostudies-arrayexpress

Inhibition of METTL3 protect against traumatic brain injury

Project description:Researchers recently identified STM2457 as a first-in-class catalytic inhibitor of METTL3 and observed a promising therapeutic effect on acute myeloid leukemia. However, it is crucial to note that the existence of the blood-brain barrier (BBB) limit the efficiency of drugs entering the brain to a large extent. In order to effectively deliver METTL3 inhibitor STM2457 to the brain, we generated RVG29 (a BBB-penetrating peptide)-based modified nanoparticle system loaded with STM2457 (abbreviated as RVG-nSTM system) that targets the brain. Specifically, a mixture of STM2457, PLGA20K-mPEG2K, and PLGA20K-PEG5K-MAL was used to prepare nSTM, which was further modified with RVG29 peptide. We investigated the impact of RVG-nSTM on neuroinflammation post-TBI in mice. We performed a total RNA-seq analysis, and observed distinct gene distributions on the volcano plot. A Venn diagram revealed that 3385 genes were differentially expressed in the TBI group compared to the sham group, and treatment with RVG-nSTM reversed the expression of 1941 of these genes . The subsequent GO and KEGG analyses showed that these 1941 genes were primarily enriched in the context of inflammatory response and inflammation-related pathways. These findings were further corroborated by the observation that RVG-nSTM treatment leads to a substantial reversal of the hyperactive microglial states that are induced by TBI . Above all, RVG-nSTM could be a promising agent for the treatment of neuroinflammation after acute brain injury.

2025-04-20 | GSE264505 | GEO

mRNA-seq of neuronal compartments in shRNA-mediated + small-molecule knockdown of Mettl3 in mouse primary cortical neurons (mPCN)

Project description:To study the effect of m6A modifications on subcellular mRNA localization we depleted m6A writer Mettl3 with shRNA and small molecule from mouse primary cortical neurons (mPCN) and sequenced neuritic and somatic compartments in parallel with scrambled shRNA control.

2023-07-12 | E-MTAB-11570 | biostudies-arrayexpress

The METTL3 RNA methyltransferase regulates gene expression in castrate resistant 22Rv1 prostate cancer cells

Project description:RNA sequencing was used to determine the effect of the STM2457 METTL3 inhibitor on prostate cancer cell gene expression.

2022-11-02 | GSE195624 | GEO

The METTL3 RNA methyltransferase regulates gene expression in castrate resistant LNCaP:C42 prostate cancer cells

Project description:RNA sequencing was used to determine the effect of the STM2457 METTL3 inhibitor on prostate cancer cell gene expression.

2022-11-02 | GSE195632 | GEO